Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $610.0M | $326.8M | $40.0M | $64.1M | $67.1M | $153.0M | $643.6M | $874.9M |
| Cost of revenue | $188.2M | $87.2M | $23.0M | $56.7M | $2.99B | $133.5M | $395.9M | $554.2M |
| Gross profit | $421.9M | $239.6M | $17.0M | $7.4M | −$2.92B | $19.4M | $247.7M | $320.7M |
| Gross margin | 69.2% | 73.3% | 42.4% | 11.6% | -4354.7% | 12.7% | 38.5% | 36.7% |
| R&D | $2.54B | $2.22B | $3.80B | $10.78B | $10.99B | $6.17B | $3.78B | $3.56B |
| Operating income | −$3.07B | −$3.27B | −$5.60B | −$15.63B | −$16.32B | −$11.97B | −$9.11B | −$5.15B |
| EBITDA | −$3.06B | −$3.26B | −$4.19B | −$13.21B | −$13.41B | −$8.86B | −$5.74B | −$5.10B |
| Net income | −$3.00B | −$3.75B | −$4.21B | −$13.68B | −$14.71B | −$7.44B | −$28.13B | −$5.13B |
| Net margin | -491.2% | -1147.9% | -10524.3% | -21319.1% | -21942.4% | -4861.7% | -4370.3% | -586.1% |
| EPS (diluted) | -34.46 | -35.81 | -35.33 | -92.86 | -94.29 | -39.29 | -126.54 | -14.45 |
Annual figures · source: Financial Modeling Prep
ANGES MG INC
No one on the platform currently holds AMGXF.
No tracked institution reports a position in AMGXF as of their last filing.
No one on the platform has traded AMGXF yet.
| $108M |
| — |
| FPHAFFaron Pharmaceuticals Oy | $3.30 | +0.00% | $210M | — |
| NWPHFNewron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.